Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179881 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708630 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708629 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL7287734 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL1448119 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL949983 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708628 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL26604823 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL13164545 | 0.95 | ABCB1 (0.47) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL29548192 | 0.93 | MCL1 (0.50) | ABCB1AGTR2KLK7MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| CN-115873000-B | Isoquinolinones and quinazolinones compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-02 | — | — | US | disclosed |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-25 | — | — | US | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| WO-2000018735-A1 | 2-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1998050030-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995009859-A1 | BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | ABCB1 2914/4885AGTR2 4036/4885KLK7 3121/4885 |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | ABCB1 4/4885AGTR2 3045/4885KLK7 2115/4885 |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | ABCB1 2914/4885AGTR2 4036/4885KLK7 3121/4885 |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | ABCB1 2983/4885AGTR2 911/4885KLK7 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.